EMORRIL CREMA 40G 1%+1.5%

EMORRIL 10 MG/G + 15 MG/G

active ingredients

1g of rectal cream contains: • hydrocortisone acetate 10 mg • lidocaine chloride 15 mg Excipients with known effects: anhydrous lanolin, methyl parahydroxybenzoate, propile parahydroxybenzoate, propylene glycol. For the full list of excipients, see paragraph 6.1.

Excellent

Anidra lanolin, methyl parahydroxybenzoate, propile parahydroxybenzoate, polysorbate 61, white vaseline, propylene glycol, carbomeri, citric acid anidro, purified water.

Therapeutic indications

Internal and external hemorrhoids; complications of hemorrhoids (eczemas, erythma, ragadi, itching, burning); pre- or post-operative treatment in abnormal surgery.

Contraindications

- Hypersensitivity to active ingredients or any of the excipients listed in paragraph 6.1. - Hypersensitivity to other local anaesthetics of amidic type and other cortisonists, although the two substances have proved relatively free of allergic or sensitive properties. - Emorril should not be administered in children under 12 years of age.

Population

Population 2 or more applications per day. Method of administration Apply with mild massage, in enough quantity to cover the sliced part. For internal applications, use the special cannula, attached to the packaging, which fits the pipe.

Conservation

This medicine does not require any special condition of conservation.

Warnings

The use, especially if prolonged, of the product can give rise to phenomena of sensitization. In this case, it is necessary to stop the treatment and advise the doctor in order to establish suitable therapy. Likewise, in case of bleeding. Keep away from the eyes. Visual disturbances With the use of systemic and topical corticosteroids, visual disturbances can be reported. If a patient occurs with symptoms such as blurred vision or other visual disorders, it is necessary to consider referral to an ophthalmologist for the evaluation of possible causes that may include cataracts, glaucoma or rare diseases such as central serum corioretinopathy (CSCR), which were reported after the use of systemic and topic corticosteroids. Emorril contains:- lanolina anidra. It can cause local skin reactions (e.g. contact dermatitis). - methyl parahydroxybenzoate and propile parahydroxybenzoate. They can cause allergic reactions (also delayed). - propylene glycol. It can cause skin irritation.

Interactions

There are no known interactions with other medicines and other forms of interaction.

Effects

Side effects due to excessive dosage or rapid absorption of lidocaine hydrochloride may occur; this is a phenomenon common to any other anesthetic. In the case of the appearance of allergic reactions (characterized by skin lesions, hives, edema and anaphylactic reactions) the application should be interrupted. Hydrocortisone acetate, like other corticosteroid preparations for topical use, can accentuate an incipient infection. In this case it is necessary to establish suitable coverage therapy. Eye pathologies: unknown frequency blurred vision (see also paragraph 4.4). Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions occurring after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk ratio of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at: http://www.agenziafarmaco.gov.it/content/come-segnalare-una-sospetta-reazione-avversa.

Overdosing

No known overdose cases.

The use of Emorril during pregnancy can be considered, if necessary.

Source: Farmadati